FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3155236465> ?p ?o ?g. }

• W3155236465 endingPage "4582" @default.
• W3155236465 startingPage "4582" @default.
• W3155236465 abstract "Abstract Introduction: TKIs have transformed the clinical history of chronic phase (CP) CML, largely replacing allo-SCT as the preferred first line treatment due to high efficacy and favorable safety profile. However some patients (pts) do not achieve an adequate response, develop resistance and/or transform to accelerated phase (AP) or blast phase (BP) CML. Response rates and duration are generally inferior beyond 2nd TKI. Allo-SCT remains an important consideration for pts with TKI failure, but outcomes are worse in advance stage CML. Thus, timing of allo-SCT in the setting of suitable HLA-matched donor for CML pt with multiple failed TKIs is important to optimize outcome. Methods: The aim of this study is to estimate residual life expectancy (RLE) for pts ages 18-65 with CP CML at initial diagnosis based on timing of allo-SCT in various settings: allo-SCT at CP1 CML, at CP2+ (after transformation to AP or BP), at AP, or at BP, or continuation of 2nd or 3rd TKI at CP1 CML, CP2+, AP or BP. The non-transplant cohort was extracted from MD Anderson (MDACC) Leukemia Department database, and the allo-SCT from Center for International Blood and Marrow Transplant Research (CIBMTR). MDACC cohort included patients initiating TKI between 1/1/2001-12/31/2013 and switched TKI due to failure as defined by European Leukemia Net (ELN) criteria; pts who underwent allo-SCT were excluded. CIBMTR cohort included pts diagnosed with CML between 1/1/2001-12/31/2013 and underwent HLA sibling matched (MRD) or unrelated donor (MUD) SCT. RLE was restricted to 10 yrs. Death due to any cause is considered an event. Results: A total of 1361 pts were included for analysis: 138 in MDACC cohort and 1223 in CIBMTR cohort. In the MDACC cohort, 77 (56%) were male and median age was 46 years (yr) (range 18.5-64.4). In the CIBMTR cohort, 703 (57%) were male and median age was 39 yrs (range 18.2-64.8). In CP1 CML multivariate analysis (MVA) which included age (younger or older than 50 yrs) demonstrated an overall mortality hazard ratio (HR) for allo-SCT compared to no SCT of 2.4 [95% CI in () hereafter, (1.2-4.9; p=0.02)] with HR for MRD SCT of 1.9 (0.9-3.8, p=0.1) and HR for MUD SCT 3.3 (1.6-6.7, p=0.001), Table 1 and Figure 1. Mean RLE was 7.1 yrs (6.8-7.5) if patients underwent allo-SCT in CP1 CML vs. 8.5 yrs (7.6-9.5) if they did not, Table 2. Patients on their 1st TKI had mean RLE of 7.0 yrs (6.6-7.5) if they underwent allo-SCT vs. 8.6 yrs (7.6-9.7) if they did not. HR for CP1 CML on their 1st TKI was 2.6 (1.1-6.0; p=0.02) for allo-SCT vs. TKI continuation. HR was 2.3 (1.0-5.3, p=0.055) and 3.0 (1.3-6.9; p=0.01) for MRD and MUD SCT, respectively. Similarly, mean RLE was 6.8 yrs (5.6-8.3) for CP1 CML pts on 2nd TKI if they underwent allo-SCT vs. 8.5 yrs (6.6-10) with TKI continuation. For CP1 CML pts on 2nd TKI, HR for allo-SCT was 2.1 (0.5-9.2; p=0.3). For CP2+ CML pts, HR was 2.0 (0.8-4.9, p=0.13) for allo-SCT on MVA. HR was 1.8 (0.7-4.6, p=0.19) and 2.2 (0.9-5.4; p=0.10) for MRD and MUD SCT, respectively. Mean RLE was 4.7 (4.1-5.3) yrs for pts undergoing allo-SCT in CP2+ CML vs. 7.4 (5.6-9.7) yrs with TKI continuation. HR was 1.1 for allo-SCT at AP (0.6-2.1; p=0.8). Mean RLE was 5.3 (4.5-6.3) yrs for AP patients undergoing allo-SCT vs. 5.6 yrs (4.0-8.2) with TKI continuation. For those in BP, a trend towards higher survival with allo-SCT compared to no SCT was noted on MVA; HR 0.7 (0.5-1.1; p=0.099). HR=0.8 (0.5-1.3); p=0.33 for MRD SCT and HR=0.7 (0.4-1.0); p=0.08 for MUD SCT when compared to no SCT. Mean RLE was 2.6 (1.8-3.8) yrs in the pts who underwent allo-SCT in BP vs. 1.5 (0.9-2.8) yrs for those who continued their TKI. Conclusion: Allo-SCT appeared to shorten survival for patients with CP1 CML but there was a trend towards benefit of SCT for those who progressed to BP CML. For CP2+ CML pts, allo-SCT trended towards worse survival. The role of allo-SCT in AP is less clear and should be determined on a case by case basis, dependent on mutation status, comorbidities, and the remaining TKI options available. However, given that this is not a clinical trial, it remains possible that patients referred for SCT may have had more aggressive disease so our results should be interpreted with caution due to the observational nature of the study and the small cohort of non-transplant pts. Considering the retrospective nature of this analysis, prospective randomized trials would be required to more formally define the optimal timing of SCT in different scenarios. ^contributed equally Download : Download high-res image (286KB) Download : Download full-size image Disclosures Lee: Pimera Inc: Consultancy; Daiichi Sankyo: Research Funding; Adaptive: Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy; Eutropics Pharmaceuticals: Research Funding; Takeda: Consultancy. Jabbour: Bristol-Myers Squibb: Consultancy. Verstovsek: Gilead: Research Funding; Promedior: Research Funding; Lilly Oncology: Research Funding; Celgene: Research Funding; Pfizer: Research Funding; Genentech: Research Funding; Bristol Myers Squibb: Research Funding; Bristol Myers Squibb: Research Funding; Blueprint Medicines Corp: Research Funding; Astrazeneca: Research Funding; Seattle Genetics: Research Funding; Blueprint Medicines Corp: Research Funding; Incyte: Research Funding; Astrazeneca: Research Funding; Pfizer: Research Funding; CTI BioPharma Corp: Research Funding; Gilead: Research Funding; Seattle Genetics: Research Funding; Incyte: Research Funding; Galena BioPharma: Research Funding; Galena BioPharma: Research Funding; Roche: Research Funding; CTI BioPharma Corp: Research Funding; Genentech: Research Funding; NS Pharma: Research Funding; Promedior: Research Funding; NS Pharma: Research Funding; Celgene: Research Funding; Lilly Oncology: Research Funding; Roche: Research Funding. Kantarjian: Amgen: Research Funding; Novartis: Research Funding; Pfizer: Research Funding; ARIAD: Research Funding; Bristol-Meyers Squibb: Research Funding; Delta-Fly Pharma: Research Funding. Cortes: Teva: Research Funding; BMS: Consultancy, Research Funding; Novartis Pharmaceuticals Corporation: Consultancy, Research Funding; ARIAD: Consultancy, Research Funding; ImmunoGen: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Sun Pharma: Research Funding." @default.
• W3155236465 created "2021-04-26" @default.
• W3155236465 creator A5000705580 @default.
• W3155236465 creator A5000750846 @default.
• W3155236465 creator A5011655907 @default.
• W3155236465 creator A5015101485 @default.
• W3155236465 creator A5021668491 @default.
• W3155236465 creator A5027193786 @default.
• W3155236465 creator A5029965689 @default.
• W3155236465 creator A5048362577 @default.
• W3155236465 creator A5048913229 @default.
• W3155236465 creator A5049385583 @default.
• W3155236465 creator A5057822243 @default.
• W3155236465 creator A5058862489 @default.
• W3155236465 creator A5059616081 @default.
• W3155236465 creator A5061026876 @default.
• W3155236465 creator A5065208117 @default.
• W3155236465 creator A5066894053 @default.
• W3155236465 creator A5074589634 @default.
• W3155236465 creator A5085521139 @default.
• W3155236465 creator A5090435894 @default.
• W3155236465 date "2017-12-07" @default.
• W3155236465 modified "2023-10-15" @default.
• W3155236465 title "Optimal Timing of Allogeneic Stem Cell Transplantation (Allo-SCT) for Chronic Myeloid Leukemia (CML) Patients in the Tyrosine Kinase Inhibitor (TKI) Era" @default.
• W3155236465 doi "https://doi.org/10.1182/blood.v130.suppl_1.4582.4582" @default.
• W3155236465 hasPublicationYear "2017" @default.
• W3155236465 type Work @default.
• W3155236465 sameAs 3155236465 @default.
• W3155236465 citedByCount "0" @default.
• W3155236465 crossrefType "journal-article" @default.
• W3155236465 hasAuthorship W3155236465A5000705580 @default.
• W3155236465 hasAuthorship W3155236465A5000750846 @default.
• W3155236465 hasAuthorship W3155236465A5011655907 @default.
• W3155236465 hasAuthorship W3155236465A5015101485 @default.
• W3155236465 hasAuthorship W3155236465A5021668491 @default.
• W3155236465 hasAuthorship W3155236465A5027193786 @default.
• W3155236465 hasAuthorship W3155236465A5029965689 @default.
• W3155236465 hasAuthorship W3155236465A5048362577 @default.
• W3155236465 hasAuthorship W3155236465A5048913229 @default.
• W3155236465 hasAuthorship W3155236465A5049385583 @default.
• W3155236465 hasAuthorship W3155236465A5057822243 @default.
• W3155236465 hasAuthorship W3155236465A5058862489 @default.
• W3155236465 hasAuthorship W3155236465A5059616081 @default.
• W3155236465 hasAuthorship W3155236465A5061026876 @default.
• W3155236465 hasAuthorship W3155236465A5065208117 @default.
• W3155236465 hasAuthorship W3155236465A5066894053 @default.
• W3155236465 hasAuthorship W3155236465A5074589634 @default.
• W3155236465 hasAuthorship W3155236465A5085521139 @default.
• W3155236465 hasAuthorship W3155236465A5090435894 @default.
• W3155236465 hasConcept C121608353 @default.
• W3155236465 hasConcept C126322002 @default.
• W3155236465 hasConcept C143998085 @default.
• W3155236465 hasConcept C170493617 @default.
• W3155236465 hasConcept C203014093 @default.
• W3155236465 hasConcept C2777408962 @default.
• W3155236465 hasConcept C2778461978 @default.
• W3155236465 hasConcept C2778729363 @default.
• W3155236465 hasConcept C2778820342 @default.
• W3155236465 hasConcept C28328180 @default.
• W3155236465 hasConcept C2911091166 @default.
• W3155236465 hasConcept C42362537 @default.
• W3155236465 hasConcept C502942594 @default.
• W3155236465 hasConcept C54355233 @default.
• W3155236465 hasConcept C71924100 @default.
• W3155236465 hasConcept C86803240 @default.
• W3155236465 hasConceptScore W3155236465C121608353 @default.
• W3155236465 hasConceptScore W3155236465C126322002 @default.
• W3155236465 hasConceptScore W3155236465C143998085 @default.
• W3155236465 hasConceptScore W3155236465C170493617 @default.
• W3155236465 hasConceptScore W3155236465C203014093 @default.
• W3155236465 hasConceptScore W3155236465C2777408962 @default.
• W3155236465 hasConceptScore W3155236465C2778461978 @default.
• W3155236465 hasConceptScore W3155236465C2778729363 @default.
• W3155236465 hasConceptScore W3155236465C2778820342 @default.
• W3155236465 hasConceptScore W3155236465C28328180 @default.
• W3155236465 hasConceptScore W3155236465C2911091166 @default.
• W3155236465 hasConceptScore W3155236465C42362537 @default.
• W3155236465 hasConceptScore W3155236465C502942594 @default.
• W3155236465 hasConceptScore W3155236465C54355233 @default.
• W3155236465 hasConceptScore W3155236465C71924100 @default.
• W3155236465 hasConceptScore W3155236465C86803240 @default.
• W3155236465 hasLocation W31552364651 @default.
• W3155236465 hasOpenAccess W3155236465 @default.
• W3155236465 hasPrimaryLocation W31552364651 @default.
• W3155236465 hasRelatedWork W2417277293 @default.
• W3155236465 hasRelatedWork W2557903862 @default.
• W3155236465 hasRelatedWork W2565311549 @default.
• W3155236465 hasRelatedWork W2592229692 @default.
• W3155236465 hasRelatedWork W2592501244 @default.
• W3155236465 hasRelatedWork W2592892140 @default.
• W3155236465 hasRelatedWork W2594006802 @default.
• W3155236465 hasRelatedWork W2595003957 @default.
• W3155236465 hasRelatedWork W2609352392 @default.
• W3155236465 hasRelatedWork W2620564407 @default.
• W3155236465 hasRelatedWork W2624394620 @default.
• W3155236465 hasRelatedWork W2773691358 @default.
• W3155236465 hasRelatedWork W2784441622 @default.
• W3155236465 hasRelatedWork W2901438977 @default.

• next